Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice

Background: There are no clinical studies comparing the efficacy of bevacizumab vs.aflibercept in association with folfiri in RAS mutated (RAS-M) metastatic colorectal cancer patients (mCRC) pretreated with folfox and bevacizumab. Patients and Methods: Consecutive RAS-M unresectable mCRC patients pr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Oncol
Egile Nagusiak: Ottaiano, Alessandro, Capozzi, Monica, Tafuto, Salvatore, De Stefano, Alfonso, De Divitiis, Chiara, Romano, Carmela, Avallone, Antonio, Nasti, Guglielmo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2019
Gaiak:
Oncology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6700318/
https://ncbi.nlm.nih.gov/pubmed/31456948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00766
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak